Comparison of Effect of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors with Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on HBA1c Level in Type 2 Diabetes in Pakistani Population

  • Muhammad Amir Misbah ul Qamar Combined Military Hospital Sialkot/National University of Medical Sciences (NUMS) Pakistan
  • Tahira Sumreen Nishtar Hospital, Multan Pakistan
  • Andaleeb Khan Combined Military Hospital Multan/National University of Medical Sciences (NUMS) Pakistan
  • Kamil Rehman Butt Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan
  • Ejaz Ali Combined Military Hospital Sialkot/National University of Medical Sciences (NUMS) Pakistan
  • Ayesha Rehman Armed Forces Institute of Cardiology/National Institute of Heart Diseases/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Keywords: Dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, Type-2 diabetes mellitus

Abstract

Objective: To compare the effect of SGLT-2 inhibitors with DPP-4 inhibitors as the add on therapy to Metformin on HBA1c level in type 2 diabetes patients in Pakistani population.

Study Design: Quasi-experimental study.

Place and Duration of Study: Combined Military Hospital Sialkot, Pakistan from Nov to Apr 2020.

Methodology: The study population comprised of 300 type-II diabetes patients with poorly controlled diabetes on Metformin managed at Combined Military Hospital Sialkot, Pakistan. Patients were divided into two groups via lottery method. GroupA received the SGLT-2 inhibitors at standard dose while group-B received the DPP-4 inhibitors at the usual standard does as recommended by the consultant medical specialist. Values of glycosylated hemoglobin were compared three months after the start of study.

Results: Mean age of the patients was 44.31 ± 5.841 years. Mean duration of type 2 diabetes mellitus in the study participants was 4.18 ± 6.369 years. HBA1c after three months of treatment in the SGLT-2 inhibitors-group was 7.01 ± 0.14 mmol/L while in the DPP-4 inhibitors-group was 7.89 ± 0.99 mmol/L. Difference between the two groups was statistically significant (pvalue <0.01). The result showed SGLT-2 inhibitors as the better option for add on therapy to Metformin as compared to DPP-4 inhibitors.

Conclusion: SGLT-2 inhibitors emerged as better option to lower the HBA1c level as compared to DPP-4 inhibitors as the add on therapy to Metformin as there was statistically significant difference in HBA1c levels after three months of therapy in both the groups.

Downloads

Download data is not yet available.
Published
2022-02-28
How to Cite
Amir Misbah ul Qamar, M., Sumreen, T., Khan, A., Butt, K., Ali, E., & Rehman, A. (2022). Comparison of Effect of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors with Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on HBA1c Level in Type 2 Diabetes in Pakistani Population. Pakistan Armed Forces Medical Journal (PAFMJ), 72(1), 25-28. https://doi.org/10.51253/pafmj.v72i1.4278
Section
Original Articles

Most read articles by the same author(s)